Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor (EGFR) Common Mutations: New Strategies.

Cancers (Basel) · 2025 · PMC12071048 · PMID 40361442

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

When compared to intravenous (IV) amivantamab, SC treatment demonstrated similar pharmacokinetics and a noninferior ORR (30.1%), with a positive trend in PFS (6.1 vs. 4.3 months), a longer median DOR (11.2 vs. 8.3 months for IV) and a better OS (HR 0.62 [0.42–0.92]).

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.